A Study to Evaluate Safety and Efficacy of PF-06826647 For Moderate To Severe Plaque Psoriasis

Summary

This multicenter study is being conducted to provide additional PF-06826647 safety and tolerability data, and to further explore the clinical efficacy of PF-06826647 in the treatment of moderate to severe plaque psoriasis. Additionally, the study is intended to enable selection of oral dose and dosing regimen for the future clinical development of PF-06826647.

Timeline

Start

2019-06-27

Primary completion

2020-05-21

Completion

2020-11-26

Outcome

Met primary endpoint

registry analysis (superiority test); Placebo QD Group vs PF-06826647 200 mg QD Group; p = 0.0004; Risk Difference (RD) 33.02 (90% CI 18.01 to 47.11); NCT03895372 ↗

Drugs

Indications